Shanghai MicuRx Pharmaceutical Co. Ltd. A
医疗健康 · 专科与仿制药
Shanghai MicuRx Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs. It is developing Contezolid (MRX-I) and Contezoilid acefosamil (MRX-4) oxazolidinone antibiotics for multidrug-resistant gram-positive bacteria; MRX-8 MRX, a polymyxin antibiotic, to target multidrug-resistant Gram-negative bacteria; MRX-5 for multidrug-resistant gram-negative bacteria; MRX-7 for multidrug-resistant gram-positive bacteria; MRX-15 and MRX-17 to treat kidney disease; MRX-18 for the treatment of COVID-19; and MRX-23 for the treatment of tumour. The company was founded in 2007 and is based in Shanghai, China.
MARKET 市值 3.41B CNY 52W ¥4.09 – ¥10.31
EODHD · Q 2026-03-31 · 同步 2026-07-12
QUALITY PEG — 营收 YoY 26.6%
▲ ROE -71.2% 营业利润率 -46.6% 净利润率 -133.7%